Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
13 January 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
09 May 2024
Events
The FTC Noncompete Rule: Where Do We Go From Here?
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Article
FTC Finalizes Rule Against Employee Noncompetes
On April 23, 2024, the Federal Trade Commission voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Health Care Law Today
FDA Continues to Take Stance That it Will Not Issue CBD Rules
The FDA recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of CBD and a new regulatory pathway is needed.